Blood Conservation in Adult Cardiac Surgery, What is the Way Forward in Today's Practice?

NCT ID: NCT02595385

Last Updated: 2015-11-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare retrograde autologous priming (RAP) of the bypass circuit to cell salvage (CS) as part of blood conservation strategies in adult cardiac surgery. It hypothesizes that RAP is at least as effective as cell salvage in terms of blood conservation but at the same time more cost effective.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiac surgery is a major blood consumer. Current evidence shows there is no benefit from transfusion for haematocrits as low as 21% and the risk of death within 30 days of surgery is almost 6 times higher for patients who receive blood. In addition, transfused patients are more likely to experience increased infections and ischaemic complications like myocardial infarction, stroke and renal compromise. While it is agreed to avoid blood transfusion when feasible, there is no current consensus on the best strategy to maintain an acceptable haemocrit and minimise the need for allogenic blood transfusion. Two of the many strategies that have been employed are Retrograde Autologous Prime (RAP) of the bypass circuit and cell salvage (CS) with reinfusion of shed blood.

This study is a prospective, randomised controlled trial with 240 patients undergoing a single procedure adult cardiac surgery that will be randomised to either full crystalloid prime volume or RAP, with or without cell salvage. There will be four study arms;

1. RAP alone
2. Cell Salvage alone
3. RAP plus cell salvage
4. Control group

Results will follow analyse of the data using a logistic regression using a design matric with blood transfused as a key explanatory variable with scope to add in patient covariables. It is expected that date will be analysed after 100 patients and if significance is achieved then the study can be terminated.

The study will aim to identify those patients that receive a blood transfusion intra or post-operatively. Symptomatology from anaemia is subjective and hard to measure. The studies linking transfusion to cardiac surgery outcomes are retrospective; despite careful risk adjustment, it is possible that these associations reflect a tendency amongst clinicians to transfuse the most critically ill patients or miss another important confounder.

In 2001, Spiess referred to current transfusion practice as a 'silent epidemic'. His description is still accurate. In 2006, almost half of all patients undergoing coronary artery bypass grafting in the united states received blood transfusion and the probability of receiving blood is greater when procedures are more complex. Although the infectious risk of blood transfusion have been successfully minimised the weight of evidence increasingly suggests that transfusing less in stable patients could prevent a significant amount of morbidity and mortality. This study will help guide management in those in whom transfusion is avoidable.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adult Cardiac Surgery Blood Transfusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RAP

Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.

Group Type ACTIVE_COMPARATOR

Retrograde Autologous Prime

Intervention Type PROCEDURE

Removal of fluid from the bypass circuit

CS

Reinfusion of shed blood during the operation

Group Type ACTIVE_COMPARATOR

Cell Salvage

Intervention Type DEVICE

Reinfusion of shed blood during the operation

RAP and CS

RAP and CS used in combination

Group Type ACTIVE_COMPARATOR

Cell Salvage

Intervention Type DEVICE

Reinfusion of shed blood during the operation

Retrograde Autologous Prime

Intervention Type PROCEDURE

Removal of fluid from the bypass circuit

Control

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cell Salvage

Reinfusion of shed blood during the operation

Intervention Type DEVICE

Retrograde Autologous Prime

Removal of fluid from the bypass circuit

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Less than 80 years of age
* Undergoing single procedure surgery
* Be on single anti-platelet therapy
* To have stopped warfarin pre-operatively with a INR of \<1.5
* Have stable coronary disease
* Have good Left Ventricular function

Exclusion Criteria

* Redo procedures
* Emergency Surgery
* Be on dual antiplatelet therapy
* Have pre-operative kidney dysfunction with eGFR \<60ml/min
* Have post-operative drainage \>200ml per hour or require re-exploration for bleeding.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Belfast Health and Social Care Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alison Murphy

Research Administrator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Reuben Jeganathan

Role: PRINCIPAL_INVESTIGATOR

Belfast Health and Social Care Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Medicine

Belfast, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

alison Murphy

Role: CONTACT

028 9063 6349

Christine Fawsett

Role: CONTACT

028 92 603107

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karen Booth

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

134964

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Feasibility Study of BMAC Enhanced CABG
NCT01074099 TERMINATED PHASE1/PHASE2
TAP-Block in Abdominal Aortic Surgery
NCT03657979 COMPLETED PHASE4